The 4 US and 1 European patents cover the design and manufacturing of the company's placental therapies. The company is targeting various applications across orthopedics, urology, and wound care.
The companies are working to bring jellyfish-derived Collagen Type Zero to North America, aiming to advance wound care and regenerative medicine with a sustainable alternative to mammalian collagen.
Exo-Top and BioXtek have signed a non-binding letter of intent to explore a partnership focused on GMP manufacturing, clinical supply, and potential commercialization of bone marrow-derived mesenchymal stem cell exosomes.
The acquisition brings expanded expertise in regenerative medicine, tissue repair, and biomaterials to Dark Horse Consulting’s service portfolio.
The partnership will focus on bringing oral mucosal stem cell therapy for diabetic foot ulcers to Florida, with FDA trials planned.
The Phase 2 study showed good results for placenta-derived cell therapy for diabetic foot ulcers complicated by PAD.
The latest additions aim to support clinicians treating smaller wounds, enhancing flexibility and workflow in surgical wound care.
Independent analysis finds NurExone’s exosomes deliver enhanced regenerative signals, showing promise for nerve repair and tissue healing applications.
The new agreement enables Vizient members broader access to BioTissue’s amniotic membrane products for diverse clinical applications.
By partnering with Fountain Life, the companies are hoping to deliver new therapies to patients in the sunshine state.
The company will produce its FDA-approved diabetic foot ulcer product and others at the new facility, creating over 200 full-time jobs.
Celularity Inc. (Nasdaq: CELU), a regenerative and cellular medicine company, announced that it received recommendation letters from the FDA's Tissue Reference Group (TRG), regarding its Natalin and Acelagraft™ products confirming that each product “appears to meet all the criteria for regulation solely…